Pathos AI Raises $237M Series E at $3B Valuation
Pathos AI announced a $237 million Series E financing at a $3 billion post-money valuation, led by Bristol Myers Squibb with participation from several unnamed returning backers. The company develops cancer drugs with its agentic AI platform, Foundry, which it says can access about 200 petabytes of oncology data. Pathos also announced agreements with Bristol Myers Squibb and Tempus AI involving Foundry access and de-identified data on Alzheimer's disease and other neurological conditions. The supplied reports do not independently validate the platform's performance claims or provide independent clinical-outcome data for Foundry-assisted development.
The round was led by Bristol Myers Squibb, and the related agreements set out concrete terms involving Foundry, clinical research and neurological-disease data. However, the reports do not independently establish how much the financing or partnerships validate the platform's performance, and no independent clinical-outcome data were provided.
Pathos AI Inc. today announced that it has raised $237 million in funding at a $3 billion valuation.
Pharmaceutical giant Bristol Myers Squibb Co. led the Series E round with participation from several unnamed returning backers. Pathos’ investor roster includes big names such as AstraZeneca plc, NEA and General Atlantic.
Pathos is developing cancer drugs using an artificial intelligence platform called Foundry. According to the company, the software has access to about 200 petabytes of oncological data. It also ingests the information generated by Pathos’ drug development programs. Foundry analyzes those datasets to help the company’s researchers pursue their work more efficiently.
Pharmaceutical research programs sometimes produce hundreds of drug candidates, molecules that can potentially be turned into medicines. Foundry uses AI agents to pinpoint the most promising molecules. From there, it identifies the patients who could benefit the most from each therapy.
Pathos also uses Foundry to plan clinical trials for the drugs that it develops. The company says that its trials are “biomarker-driven.” Biomarkers are biological phenomena that can provide insight into the effectiveness of a drug. They take a wide variety of forms ranging from proteins to patient metrics such as blood pressure.
#Pathos AI#Bristol Myers Squibb#Tempus AI#Foundry#AstraZeneca#JSKN016